There is a first time for everything. mRNA is a developing technology, BioNTech was researching it for fighting cancer. When the Covid crisis struck, a lot of c

There is a first time for everything. mRNA is a developing technology, BioNTech was researching it for fighting cancer. When the Covid crisis struck, a lot of companies were focusing their efforts on a vaccine. In contrast to what many claim, vaccines are not making companies rich, so research in this field is rather slow. The pressing circumstances, as you phrased it, caused several companies in applying mRNA technology for the SARS-Cov-2 vaccination. Otherwise they might not have pushed in that direction quickly. The requirements for approval are the same ones as for any other vaccine, they have to run through the same procedures and tests.